This page is updated frequently with new Lms-related patent applications.
|| List of recent Lms-related patents
|Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide|
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center
|T cell immunotherapy specific for wt-1|
The present disclosure provides high affinity and enhanced affinity t cell receptors specific for human wilms tumor protein 1 (wt-1) epitopes for use in treating diseases or disorders, such as cancer cells that overexpress wt-1.. .
Fred Hutchinson Cancer Research Center
|Oral delivery of drug actives in laboratory animals using fast-dissolving oral films|
The invention provides a method of orally delivering a pharmaceutical composition to a test animal, and a method of evaluating for treatment or diagnosis of a medical condition, a pharmaceutical composition administered orally to a test animal, including administering to the test animal an effective amount of an oral thin film including the pharmaceutical composition, wherein orally delivering a pharmaceutical composition to the test animal is performed to evaluate the safety and efficacy of the pharmaceutical composition, and wherein reduced trauma is associated with administration of the pharmaceutical composition by oral thin film to the test animal, compared to a gavage administration. Further, a method of treatment of an alcohol uptake disorder (aud) in a patient is provided, including administering to the patient afflicted therewith an effective amount of an oral thin film formulation of ivermectin..
|Organic compositions to treat beta-catenin-related diseases|
The present disclosure relates to rnai agents useful in methods of treating beta-catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a rnai agent to beta-catenin.. .
|Disintegrable oral films|
A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent.
|Packaging structure for biomedical films|
A multilayer structure for the packaging of biomedical films, in particular oral films, is described, said multilayer structure comprising cold-adhesive laminates and at least partly non-adhesive supporting layers which are organized in a specific stratified structure. The film packaged therein is effectively isolated from the external environment and protected from accidental mechanical stresses; the packaging process is low-cost and particularly attentive to the delicate structural characteristics of biomedical films..
|Transoral methods and compositions for wrinkle reduction and cosmetic lip and facial augmentation|
The purpose of this patent is to teach the methods of application and compositions of cosmetic and therapeutic products for reducing wrinkle appearance and augmenting certain compartments of the facial integument of a mammal, especially a human. These methods and compositions utilize the hypodermis-targeted release from bioadhesive oral films, pastes or patches applied to oral mucosa or teeth for the purpose of improving the appearance or health of the lips and facial skin..
|Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, producing said cell, and said nucleic acid construct|
A cell of the present invention contains a nucleic acid construct encoding a wt1 gene product or a fragment of the wt1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the wt1 gene product and (ii) only aug as a functional start codon.
Lms topics: Semiconductor, Electronic Device, High Energy, Alkali Metal, Sodium Ion Battery, Homogeneous, Aqueous Solution, Surface Treatment, Plastic Film, Flow Control, Vibration Sensor, Semiconductor Device, Heterogeneous, Chromophore, Fluorescence
Follow us on Twitter
This listing is a sample listing of patent applications related to Lms for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Lms with additional patents listed. Browse our RSS directory or Search for other possible listings.